- Lumos Pharma press release ( NASDAQ: LUMO ): Q2 GAAP EPS of -$0.94 beats by $0.04 .
- Revenue of $0.4M (+3900.0% Y/Y) beats by $0.38M .
For further details see:
Lumos Pharma GAAP EPS of -$0.94 beats by $0.04, revenue of $0.4M beats by $0.38MFor further details see:
Lumos Pharma GAAP EPS of -$0.94 beats by $0.04, revenue of $0.4M beats by $0.38MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company w...
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the...
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted f...